news
EC approves Libtayo® for metastatic cervical cancer
The European Commission has approved Libtayo® for cervical cancer and disease progression while on or after platinum-based chemotherapy, due to positive Phase III trial results.
List view / Grid view
Cervical cancer
article
Merck’s Keytruda®: update on trials and outcomes
EPR’s Anna Begley summarises some of the key results from trials of Merck’s Keytruda® (pembrolizumab) cancer treatment.
news
Libtayo® improves overall survival in advanced cervical cancer patients
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
news
Immunotherapies to treat cervical cancer show promise in Phase II trials
Novel programmed cell death protein 1 immunotherapies for cervical cancer have demonstrated success in two Phase II clinical trials in the US.
news
Cervical dysplasia treatment device approved for global Phase III trial
The cervical dysplasia drug-device product, APL-1702 (Cevira®), offers an alternative to surgery and has been approved to start a clinical trial in China and several other countries.
news
Researchers find one dose of HPV vaccine as effective as other regimens
A study investigating the effectiveness of HPV vaccines has revealed that a single dose is as successful at preventing cervical cancer as multiple doses.
news
Effectiveness of HPV vaccines Cervarix and Gardasil under question
Analysis of the designs of Phase II and III efficacy trials for HPV vaccines suggest they overstated their effectiveness against cervical cancer, according to researchers.
news
Cervical cancer vaccine market set to increase at 12.1 percent CAGR
A recent report has predicted that the cervical cancer vaccine market will increase to $6bn by the end of the forecast period.
news
Roche’s medicine Avastin plus chemotherapy improved survival in women with advanced cervical cancer, compared to chemotherapy alone
2 June 2013 | By Roche
Results of study GOG240...
